If you are in an emergency, in crisis or need someone to talk to, there is help.
View Crisis Resouces
CAMH Research Discoveries
CAMH has been at the leading edge of breakthrough mental health research for over 50 years, with each new finding giving rise to new methodologies, treatments and hope.
A Long History of New Discoveries
To understand where we're going, it's important to know how far we've come. The discoveries we make today would not be possible without the wealth of knowledge generated through decades of research by CAMH scientists in their ongoing pursuit to transform the nature of preventative care and treatment for patients worldwide.
BrainBuzz Newsletter
Catch up on the latest news, groundbreaking discoveries and special features about CAMH research, studies and the people behind the work.
Read moreResearch Milestones
2008
CAMH researchers discover the first concrete genetic linkage to schizophrenia via a subtype of the disease called Deletion Syndrome (22qDS).
2010
CAMH scientists demonstrate that mindfulness-based cognitive therapy provides equivalent protection against depressive relapse as traditional antidepressant medication.
2010
CAMH scientists discover higher levels of a brain protein called monoamine oxidase A (MAO-A) in women after childbirth, providing a possible explanation for why postpartum blues and clinical depression occur. Using this knowledge, scientists begin developing supplements to target this loss of nutrients and lower the risk of postpartum depression.
2011
Using brain imaging and genetics, CAMH scientists identify a variation of a gene that may play a role in late-onset Alzheimer's disease.
2011
CAMH launches first mobile research laboratory to study mental health in rural, remote and First Nations communities across Ontario.
2012
The Campbell Family Mental Health Research Institute at CAMH, dedicated to understanding brain structure and function to identify the causes and best treatments for mental illness, including addiction, officially opens.
2012
CAMH opens the Temerty Centre for Therapeutic Brain Intervention to research innovative non-invasive brain stimulation treatments, including repetitive transcranial magnetic stimulation and magnetic stimulation therapy.
2014
Campbell Institute scientists are part of a large international team that identifies 108 genetic variants associated with schizophrenia.
2015
Through brain imaging, Campbell Institute scientists show brain inflammation occurring during major depressive episodes. The finding provides a potential new target for depression treatment, as current therapeutics do not target inflammation.
1974
Dr. Philip Seeman discovers the effectiveness of antipsychotic drugs is directly related to their ability to block the dopamine D2 receptor. This opens the way to a scientific explanation for the drugs’ reactions. His papers are among the most highly cited in the schizophrenia literature.
1977
The Addiction Research Foundation (now part of CAMH) is named the first World Health Organization (WHO) Collaborating Centre in the field of drugs and alcohol. This international collaborative role continues today; in 2008, CAMH research underlies WHO’s adoption of the Global Strategy to Reduce the Harmful Use of Alcohol.
1977
Addiction Research Foundation develops RIDE (Reduce Impaired Driving in Etobicoke) as a pilot project beginning Oct. 1, 1977. Today RIDE (now Reduce Impaired Driving Everywhere) is used by police across the country.
1992
Opening of Canada’s first PET (positron emission tomography) Centre dedicated to medical imaging research in mental illness. Over the following decade, CAMH’s PET Centre develops several ligands (illuminating radiotracer agents) commonly used in human neuroscience.
1998
Merger of four organizations to form the Centre for Addiction and Mental Health (CAMH): Queen Street Mental Health Centre, Clarke Institute of Psychiatry, Donwood Institute, and Addiction Research Foundation—a pioneering move recognizing the interconnected nature of mental illness and addiction.
2005
CAMH scientists identify a new variant of the gene that causes Rett syndrome, a serious neurodevelopmental disorder that affects almost exclusively females. The discovery is translated into a licensed diagnostic tool for the disease currently available to the public.
2006
CAMH PET studies reveal that most antidepressants miss the key target—serotonin receptors—for treating clinical depression. The discovery establishes a standard that anti-depressants being developed for the market be 80 per cent effective in hitting this target.
2006
Opening of the Krembil Family Epigenetics Laboratory at CAMH—the first psychiatric epigenetics lab in the world exploring the “switches” that turn genes on or off, for example, the impact of nutrition and stress.
2008
CAMH opens Canada’s first pharmacogenetics clinic, dedicated to understanding the genetics of people’s response to psychiatric medication and the side-effects they experience. Its vision is a new era of personalized medicine for people living with all forms of mental illness, including addiction.
2008
CAMH researchers discover the first concrete genetic linkage to schizophrenia via a subtype of the disease called Deletion Syndrome (22qDS).
2010
CAMH scientists demonstrate that mindfulness-based cognitive therapy provides equivalent protection against depressive relapse as traditional antidepressant medication.
2010
CAMH scientists discover higher levels of a brain protein called monoamine oxidase A (MAO-A) in women after childbirth, providing a possible explanation for why postpartum blues and clinical depression occur. Using this knowledge, scientists begin developing supplements to target this loss of nutrients and lower the risk of postpartum depression.
2011
Using brain imaging and genetics, CAMH scientists identify a variation of a gene that may play a role in late-onset Alzheimer's disease.
2011
CAMH launches first mobile research laboratory to study mental health in rural, remote and First Nations communities across Ontario.
2012
The Campbell Family Mental Health Research Institute at CAMH, dedicated to understanding brain structure and function to identify the causes and best treatments for mental illness, including addiction, officially opens.
2012
CAMH opens the Temerty Centre for Therapeutic Brain Intervention to research innovative non-invasive brain stimulation treatments, including repetitive transcranial magnetic stimulation and magnetic stimulation therapy.
2014
Campbell Institute scientists are part of a large international team that identifies 108 genetic variants associated with schizophrenia.
2015
Through brain imaging, Campbell Institute scientists show brain inflammation occurring during major depressive episodes. The finding provides a potential new target for depression treatment, as current therapeutics do not target inflammation.
1974
Dr. Philip Seeman discovers the effectiveness of antipsychotic drugs is directly related to their ability to block the dopamine D2 receptor. This opens the way to a scientific explanation for the drugs’ reactions. His papers are among the most highly cited in the schizophrenia literature.
1977
The Addiction Research Foundation (now part of CAMH) is named the first World Health Organization (WHO) Collaborating Centre in the field of drugs and alcohol. This international collaborative role continues today; in 2008, CAMH research underlies WHO’s adoption of the Global Strategy to Reduce the Harmful Use of Alcohol.
1977
Addiction Research Foundation develops RIDE (Reduce Impaired Driving in Etobicoke) as a pilot project beginning Oct. 1, 1977. Today RIDE (now Reduce Impaired Driving Everywhere) is used by police across the country.
1992
Opening of Canada’s first PET (positron emission tomography) Centre dedicated to medical imaging research in mental illness. Over the following decade, CAMH’s PET Centre develops several ligands (illuminating radiotracer agents) commonly used in human neuroscience.
1998
Merger of four organizations to form the Centre for Addiction and Mental Health (CAMH): Queen Street Mental Health Centre, Clarke Institute of Psychiatry, Donwood Institute, and Addiction Research Foundation—a pioneering move recognizing the interconnected nature of mental illness and addiction.
2005
CAMH scientists identify a new variant of the gene that causes Rett syndrome, a serious neurodevelopmental disorder that affects almost exclusively females. The discovery is translated into a licensed diagnostic tool for the disease currently available to the public.
2006
CAMH PET studies reveal that most antidepressants miss the key target—serotonin receptors—for treating clinical depression. The discovery establishes a standard that anti-depressants being developed for the market be 80 per cent effective in hitting this target.
2006
Opening of the Krembil Family Epigenetics Laboratory at CAMH—the first psychiatric epigenetics lab in the world exploring the “switches” that turn genes on or off, for example, the impact of nutrition and stress.
2008
CAMH opens Canada’s first pharmacogenetics clinic, dedicated to understanding the genetics of people’s response to psychiatric medication and the side-effects they experience. Its vision is a new era of personalized medicine for people living with all forms of mental illness, including addiction.
Research Reports
CAMH Research Reports highlight discoveries and accomplishments from past years.
Reports & Books
Download or order books, reports, studies and brochures on topics ranging from lower-risk cannabis use to homelessness.
Explore moreCAMH on PubMed
View CAMH scientific and academic articles available on the U.S. National Center for Biotechnology Information PubMed database.
Explore moreCan we count on your support?
Donate to help us improve mental health care for everyone.
Keep in touch with CAMH
Keep your finger on our pulse – latest CAMH news, discoveries and ways to get involved delivered to your inbox.
Please select a newsletter
Please complete the following:
Required Fields
Thanks for Subscribing.
We look forward to keeping you informed, inspired and involved in all things CAMH.
Help us change mental health care forever.
Every donation moves us closer to a future where no one is left behind.